Progress of Nanotechnology in Diabetic Retinopathy Treatment.


Journal

International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847

Informations de publication

Date de publication:
2021
Historique:
received: 27 12 2020
accepted: 05 02 2021
entrez: 4 3 2021
pubmed: 5 3 2021
medline: 27 3 2021
Statut: epublish

Résumé

Diabetic retinopathy (DR) is a chronic diabetes complication that progressively manifests itself as blurred vision, eye floaters, distorted vision, and even partial or total loss of vision as a result of retinal detachment in severe cases. Clinically, patients who have undergone variations in the microcirculation of the ocular fundus are treated with laser photocoagulation to improve the circulation of retina; but for patients with macular edema, anti-vascular endothelial growth factor (anti-VEGF) drugs are generally injected to eliminate macular edema and improve vision. The worst cases are patients with fundus hemorrhage or proliferative vitreoretinopathy, for whom vitrectomy has been performed. At present, these clinical treatment methods have widely been used, providing satisfactory results. However, considering the low bioavailability and potential side effects of drugs and the inevitable risks in major surgery, DR prevention, and treatment as well as nerve tissue regeneration in the later stage have always been the focus of research. In recent years, nanotechnology has been increasingly applied in the medical field, leading to new ideas for DR treatment. This study aims to systematically review the research progress of nanotechnology in DR treatment.

Identifiants

pubmed: 33658779
doi: 10.2147/IJN.S294807
pii: 294807
pmc: PMC7917322
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1391-1403

Informations de copyright

© 2021 Liu and Wu.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest for this work.

Références

N Engl J Med. 1993 Sep 30;329(14):977-86
pubmed: 8366922
Biomaterials. 2014 Mar;35(9):2837-50
pubmed: 24439407
Ophthalmologica. 1990;200(3):133-41
pubmed: 2345627
Artif Cells Nanomed Biotechnol. 2018 Jun;46(4):805-814
pubmed: 28691584
Int Ophthalmol. 2019 Sep;39(9):1973-1980
pubmed: 30284092
Prog Retin Eye Res. 2013 Sep;36:172-98
pubmed: 23603534
Curr Pharm Des. 2018;24(12):1270-1276
pubmed: 29484982
Semin Ophthalmol. 2014 Sep-Nov;29(5-6):290-300
pubmed: 25325854
Curr Eye Res. 2013 Dec;38(12):1261-5
pubmed: 23972000
Int J Mol Sci. 2020 Dec 18;21(24):
pubmed: 33352955
ACS Appl Mater Interfaces. 2017 Nov 1;9(43):37623-37636
pubmed: 28990762
Arch Ophthalmol. 1985 Dec;103(12):1796-806
pubmed: 2866759
Prog Retin Eye Res. 2016 Sep;54:1-29
pubmed: 27102270
Small. 2019 Oct;15(40):e1902776
pubmed: 31402576
Nanomedicine. 2012 Aug;8(6):1034-41
pubmed: 22115598
Adv Drug Deliv Rev. 2011 Oct;63(13):1172-85
pubmed: 21914455
Int J Pharm. 2010 Jun 30;393(1-2):167-75
pubmed: 20362042
J Control Release. 2013 Dec 28;172(3):625-33
pubmed: 24126220
Ophthalmic Surg Lasers Imaging Retina. 2016 Oct 1;47(10):914-923
pubmed: 27759857
Acta Ophthalmol. 2017 Dec;95(8):e746-e750
pubmed: 27288252
Lupus. 2015 Jul;24(8):835-45
pubmed: 25593049
J Clin Invest. 2010 Nov;120(11):4065-76
pubmed: 20921623
Ophthalmology. 2003 Sep;110(9):1677-82
pubmed: 13129861
Biochem Biophys Res Commun. 2006 Nov 24;350(3):514-20
pubmed: 17027651
Gene Ther. 1997 Sep;4(9):891-900
pubmed: 9349425
Graefes Arch Clin Exp Ophthalmol. 1987;225(6):385-90
pubmed: 3678848
Int J Ophthalmol. 2014 Feb 18;7(1):1-7
pubmed: 24634856
J Control Release. 2012 Jul 20;161(2):505-22
pubmed: 22353619
Artif Cells Blood Substit Immobil Biotechnol. 2010 May;38(3):143-9
pubmed: 20367549
J Photochem Photobiol B. 2019 Jul;196:111502
pubmed: 31129511
ACS Appl Mater Interfaces. 2016 Mar 23;8(11):6834-40
pubmed: 26926578
Front Bioeng Biotechnol. 2020 Feb 25;8:144
pubmed: 32158755
Int J Mol Sci. 2018 Jun 20;19(6):
pubmed: 29925789
Biomaterials. 2011 Mar;32(7):1865-71
pubmed: 21145587
Curr Eye Res. 2010 Jul;35(7):537-52
pubmed: 20597640
Nanotechnology. 2011 Jan 28;22(4):045101
pubmed: 21169662
Pharmacol Res. 2016 Sep;111:713-720
pubmed: 27475885
Colloids Surf B Biointerfaces. 2010 Dec 1;81(2):412-21
pubmed: 20719479
Rom J Ophthalmol. 2016 Jan-Mar;60(1):31-6
pubmed: 27220230
Eur J Ophthalmol. 2016 Mar-Apr;26(2):174-81
pubmed: 26350989
Front Physiol. 2016 Jun 01;7:200
pubmed: 27313539
Diabetes. 2000 Jun;49(6):1016-21
pubmed: 10866055
Am J Ophthalmol. 2000 Jan;129(1):27-32
pubmed: 10653409
Endocrine. 2009 Aug;36(1):45-51
pubmed: 19390997
Ophthalmology. 1988 Dec;95(12):1673-9
pubmed: 3231435
J Cell Mol Med. 2019 Jul;23(7):4723-4737
pubmed: 31094072
BMC Complement Altern Med. 2015 Feb 05;15:16
pubmed: 25652875
J Mater Chem B. 2017 Apr 7;5(13):2375-2379
pubmed: 28966790
Diabetes Care. 2013 Mar;36(3):656-61
pubmed: 23093662
Colloids Surf B Biointerfaces. 2011 Nov 1;88(1):150-7
pubmed: 21764568
Dev Ophthalmol. 2007;39:96-110
pubmed: 17245081
Biomaterials. 2009 Oct;30(31):6341-50
pubmed: 19698986
Pharm Dev Technol. 2019 Jul;24(6):663-670
pubmed: 30516412
Nephrol Dial Transplant. 2012 Jul;27(7):2702-11
pubmed: 22167593
Gene Ther. 1998 Jul;5(7):930-7
pubmed: 9813664
J Am Soc Nephrol. 2004 Dec;15(12):3073-82
pubmed: 15579510
Biotechnol Bioeng. 2007 Apr 15;96(6):1139-54
pubmed: 17009321
J Biomed Mater Res A. 2015 Aug;103(8):2621-7
pubmed: 25611196
Diabetes Care. 2017 Aug;40(8):1111-1120
pubmed: 28733376
Nanomedicine. 2012 Jul;8(5):784-91
pubmed: 21945900
J Ophthalmol. 2019 Jan 10;2019:3120960
pubmed: 30733873
Diabetes Care. 1985 Jan-Feb;8(1):57-63
pubmed: 4038642
J Diabetes Res. 2016;2016:3102962
pubmed: 27672664
Microsc Res Tech. 2013 Sep;76(9):936-41
pubmed: 23913581
Ophthalmology. 2016 Aug;123(8):1722-1730
pubmed: 27236272
Vestn Oftalmol. 2019;135(5. Vyp. 2):272-277
pubmed: 31691672
Arch Pharm Res. 2014 Mar;37(3):404-11
pubmed: 23828754
Curr Eye Res. 2017 Aug;42(8):1169-1173
pubmed: 28339297
Eur J Pharm Sci. 2013 Nov 20;50(3-4):341-52
pubmed: 23933615
Int Ophthalmol. 2008 Feb;28(1):29-34
pubmed: 17619829
J Diabetes Res. 2018 Feb 8;2018:2852398
pubmed: 29577044
Mol Biol Rep. 2013 Jun;40(6):3883-90
pubmed: 23588957
Int J Pharm. 2014 Jan 30;461(1-2):64-73
pubmed: 24275449

Auteurs

Yuxin Liu (Y)

Student Affairs Department, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China.

Na Wu (N)

Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China.
Clinical Skills Practice Teaching Center, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH